

Hui Yu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3125886/publications.pdf>

Version: 2024-02-01

34
papers

2,931
citations

361413

20
h-index

395702

33
g-index

34
all docs

34
docs citations

34
times ranked

4839
citing authors

#	ARTICLE	IF	CITATIONS
1	NaPi2b expression in a large surgical Non-Small Cell Lung Cancer (NSCLC) cohort. <i>Clinical Lung Cancer</i> , 2022, 23, e90-e98.	2.6	3
2	Loss of STING expression is prognostic in non-small cell lung cancer. <i>Journal of Surgical Oncology</i> , 2022, 125, 1042-1052.	1.7	8
3	Testing Cancer Immunotherapy in a Human Immune System Mouse Model: Correlating Treatment Responses to Human Chimerism, Therapeutic Variables and Immune Cell Phenotypes. <i>Frontiers in Immunology</i> , 2021, 12, 607282.	4.8	19
4	Characterization of Tumor-Associated Macrophages and the Immune Microenvironment in Limited-Stage Neuroendocrine-High and -Low Small Cell Lung Cancer. <i>Biology</i> , 2021, 10, 502.	2.8	21
5	Programmed Cell Death Ligand 1 Expression in Resected Non-Small Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 22, e555-e562.	2.6	1
6	Multi-Institutional Prospective Validation of Prognostic mRNA Signatures in Early Stage Squamous Lung Cancer (Alliance). <i>Journal of Thoracic Oncology</i> , 2020, 15, 1748-1757.	1.1	21
7	Role of mTOR As an Essential Kinase in SCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1522-1534.	1.1	12
8	Neuroendocrine subtypes of small cell lung cancer differ in terms of immune microenvironment and checkpoint molecule distribution. <i>Molecular Oncology</i> , 2020, 14, 1947-1965.	4.6	48
9	EGFR-directed monoclonal antibodies in combination with chemotherapy for treatment of non-small-cell lung cancer: an updated review of clinical trials and new perspectives in biomarkers analysis. <i>Cancer Treatment Reviews</i> , 2019, 72, 15-27.	7.7	37
10	Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer. <i>Cancer Immunology Research</i> , 2019, 7, 630-643.	3.4	217
11	Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma. <i>Journal of Thoracic Oncology</i> , 2019, 14, 25-36.	1.1	68
12	T cell immunoglobulin and mucin-domain containing-3 in non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2019, 8, 895-906.	2.8	29
13	Early detection of lung cancer by using an autoantibody panel in Chinese population. <i>Oncotarget</i> , 2018, 7, e1384108.	4.6	54
14	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. <i>Lung Cancer</i> , 2018, 125, 115-120.	2.0	29
15	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. <i>Clinical Lung Cancer</i> , 2018, 19, 450-456.	2.6	4
16	CD44 Facilitates Epithelial-to-Mesenchymal Transition Phenotypic Change at Acquisition of Resistance to EGFR Kinase Inhibitors in Lung Cancer. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 2257-2265.	4.1	41
17	PD-L1 Immunohistochemistry Comparability Study in Real-Life Clinical Samples: Results of Blueprint Phase 2 Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1302-1311.	1.1	589
18	Preselection of lung cancer cases using FGFR1 mRNA and gene copy number for treatment with ponatinib. <i>Journal of Clinical Oncology</i> , 2018, 36, 12095-12095.	1.6	2

#	ARTICLE	IF	CITATIONS
19	Comparison the anti-tumor effect of pyrotinib, afatinib and T-DM1 in lung cancer organoids and PDX models with HER2 mutation.. Journal of Clinical Oncology, 2018, 36, e24281-e24281.	1.6	4
20	Heterogeneity in Immune Marker Expression after Acquisition of Resistance to EGFR Kinase Inhibitors: Analysis of a Case with Small Cell Lung Cancer Transformation. Journal of Thoracic Oncology, 2017, 12, 1015-1020.	1.1	20
21	A Prospective, Multi-institutional, Pathologist-Based Assessment of 4 Immunohistochemistry Assays for PD-L1 Expression in Non-Small Cell Lung Cancer. JAMA Oncology, 2017, 3, 1051.	7.1	658
22	LAG-3 Protein Expression in Non-Small Cell Lung Cancer and Its Relationship with PD-1/PD-L1 and Tumor-Infiltrating Lymphocytes. Journal of Thoracic Oncology, 2017, 12, 814-823.	1.1	192
23	Therapy-induced E-cadherin downregulation alters expression of programmed death ligand-1 in lung cancer cells. Lung Cancer, 2017, 109, 1-8.	2.0	27
24	MHC class II expression in lung cancer. Lung Cancer, 2017, 112, 75-80.	2.0	80
25	PD-L1 Expression by Two Complementary Diagnostic Assays and mRNA In Situ Hybridization in Small Cell Lung Cancer. Journal of Thoracic Oncology, 2017, 12, 110-120.	1.1	108
26	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. Theranostics, 2017, 7, 4753-4762.	10.0	25
27	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. BioMed Research International, 2017, 2017, 1-7.	1.9	13
28	PD-1, PD-L1 Protein Expression in Non-Small Cell Lung Cancer and Their Relationship with Tumor-Infiltrating Lymphocytes. Medical Science Monitor, 2017, 23, 1208-1216.	1.1	49
29	Potential effect of spliceosome inhibition in small cell lung cancer irrespective of the MYC status. PLoS ONE, 2017, 12, e0172209.	2.5	13
30	Evaluation of CD73 in lung cancer.. Journal of Clinical Oncology, 2017, 35, e14525-e14525.	1.6	0
31	PD-L1 Expression in Lung Cancer. Journal of Thoracic Oncology, 2016, 11, 964-975.	1.1	329
32	Heterogeneity of EGFR Aberrations and Correlation with Histological Structures: Analyses of Therapy-Naive Isogenic Lung Cancer Lesions with EGFR Mutation. Journal of Thoracic Oncology, 2016, 11, 1711-1717.	1.1	12
33	Lymphocyte activation gene-3, an important immune checkpoint in cancer. Cancer Science, 2016, 107, 1193-1197.	3.9	168
34	Fibroblast Growth Factor Receptor 1 and Related Ligands in Small-Cell Lung Cancer. Journal of Thoracic Oncology, 2015, 10, 1083-1090.	1.1	30